| Lay Summary
|
Glaucoma is a leading cause of irreversible blindness. The term ‘glaucoma’ refers to a group of heterogenous pathologies that result in excavation of the eye, progressive damage to the retinal ganglion cells (RGCs), optic nerve damage, and subsequent visual impairment. There are currently no treatments that cure glaucoma; however, medications that reduce intraocular pressure (IOP) may slow or prevent disease progression. There have been several clinical studies that have assessed synthetic cannabinoids on glaucoma. Many of these have shown significant lowering of IOP however the effects can be short lived and the drugs have been shown to cause side effects that patients were not able to tolerate including nausea, confusion, euphoria and dizziness.
ART27.13 is a synthetic, peripherally selective cannabinoid with minimal brain penetration therefore it should not cause the unwanted side effects seen in other cannabinoids. This trial will investigate the safety and tolerability of treatment with capsulated ART27.13 at a dose of 600ug over a three week treatment period and whether is reduces IOP. |
| Document | Version |
| Participant Information Sheet | DREAM_Participant Information Sheet_v4.0 Final_10032026 |